Changes to This Summary (04/18/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Hormone therapy (estrogen plus progestin) as a new subsection.
Revised text to state that based on fair evidence, conjugated equine estrogens do not affect that incidence of, or survival from invasive colorectal cancer.
Added text about the Women's Health Initiative (WHI) trial that examined the effect of combined estrogen and progestin therapy and estrogen-only therapy on colorectal cancer incidence and mortality (cited Simon et al. as reference 73).
Added text to state that the estrogen-only intervention component of the WHI was conducted among women who had a hysterectomy, with colorectal cancer incidence included as a secondary trial endpoint; colorectal cancer incidence was not decreased among women who had taken estrogens (cited Ritenbaugh et al. as reference 74).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.